Chimeric Antibody

A recombinant or genetically engineered antibody—e.g., a mouse monoclonal—which contains polypeptides or domains from a different species—e.g., humans—often introduced to reduce the antibody’s immunogenicity
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
- Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
The sample size is increased from 15 to 50 microliters, increasing the chances of "recovery." Other modifications include signal amplification and genetic re-engineering of the chimeric antibody itself to improve precision and performance.
Novak-Hofer et al., "Production and characterization of a mouse human chimeric antibody directed against human neuroblastoma," International Journal of Cancer, vol.
Hassan et al., "Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin," Cancer Immunity, vol.
In their pilot study, seven dogs with oral malignant melanoma (OMM) and two dogs with undifferentiated sarcoma were treated with the chimeric antibody every two weeks.
However, the chimeric antibody still induced human antibody responses, which is an important consideration when repeated dosing is required for, for example, scouting studies prior to therapy.
In this report, we used the unique bioengineering technology of silkworms and established a chimeric antibody (CH-CSLEX-1) with a human IgG constant region and the original binding site of the CSLEX-1 mouse IgM monoclonal antibody.
Unituxin (dinutuximab) is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain kappa.
[11.] Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
Expression of chimeric antibody in mammalian cells using dicistronic expression vector.
The product is a monoclonal chimeric antibody developed to treat neuroblastoma, a malignant tumor developing from nerve tissue and most common in children below five years.